Expert Review of Hematology

Papers
(The median citation count of Expert Review of Hematology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Treatment patterns and blood count control in 10,112 patients with polycythemia vera63
Hemophagocytic lymphohistiocytosis in Egyptian children: diagnosis, treatment challenges, and outcome54
From bench to bedside: bridging the gaps in best practices for real-world chronic myeloid leukemia care40
What is the future of digital tools to help manage pain in sickle cell disease patients?39
Do we need more guidance on thrombophilia testing? Challenges and special considerations36
Upfront therapy for diffuse large B-cell lymphoma: looking beyond R-CHOP33
Hematological parameters and X-ray exposure among medical radiation workers: a systematic review and meta-analysis26
Are we closer to a standard of care for Richter’s syndrome? Novel treatments on the horizon24
The evolving management algorithm for the patient with newly diagnosed cold agglutinin disease23
Immune thrombocytopenia and pregnancy: challenges and opportunities in diagnosis and management23
Treating sickle cell disease in resource-limited sub-Saharan Africa: recent strategies and recommendations in addressing the gaps for the provision of evidence-based management21
Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitors among elderly patients ≥65 years in chronic lymphocytic l21
Past, present, and future of orthopedic surgery in hemophilia: looking to a world without bleeding and arthropathy in the near future19
Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations18
Allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: current status and future directions mainly focusing on a Chinese perspective18
Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B18
BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia18
Correlation between hematocrit and the risk of common human cancers: results of a 1999–2020 observational survey and Mendelian randomization analysis18
Efanesoctocog alfa for the prevention and treatment of bleeding in patients with hemophilia A15
The future of siRNA-mediated approaches to treat von Willebrand disease15
Improving endpoints for sickle cell disease clinical trials: retaining consistency and clinical benefit15
Extended post-discharge thromboprophylaxis in hospitalized COVID-19 patients15
Rilzabrutinib for persistent or chronic immune thrombocytopenia (ITP): a Bruton tyrosine kinase inhibitor that can target multiple pathophysiological pathways14
Evaluating ropeginterferon alfa-2b for the treatment of adults with polycythemia vera14
Current trends and future artificial intelligence applications in transfusion medicine: a bibliometric analysis14
Sickle cell disease and infertility risks: implications for counseling and care of affected girls and women14
Screening and interventional strategies for the late effects and toxicities of hematological malignancy treatments in pediatric survivors14
ADAMTS13 activity and clinical outcomes: a targeted literature review in congenital thrombotic thrombocytopenic purpura and other related thrombotic conditions13
Late effects of hemopoietic stem cell transplant for sickle cell disease: monitoring and management13
Can minimal residual disease be used to tailor therapy duration for chronic lymphocytic leukemia patients?12
Efficacy and safety of phosphatidylinositol 3-kinase inhibitors in patients with chronic lymphocytic leukemia: a meta-analysis and systematic review12
BCL-2 inhibition in acute myeloid leukemia: resistance and combinations12
Voxelotor for the treatment of sickle cell disease in pediatric patients12
Impact of atrial fibrillation in onco-hematological patients in Europe: a targeted literature review12
Patient-centered care in von Willebrand disease: are we there yet?12
Review, conceptual model, and gap analysis of transfusion burden in hematological diseases12
New directions to develop therapies for people with hemophilia12
Bone marrow aspirate or biopsy for multiple myeloma: when percentages matter!12
Transfusion efficacy and adverse events of a restrictive transfusion strategy in patients with acute upper gastrointestinal bleeding11
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: facilitating research through infrastructure, workforce, resources and funding11
Apparent plateaus during iron chelation in transfusion-dependent β-thalassemia: interpretation and clinical implications11
Development and internal validation of a prediction model for patients with hematologic diseases of fall risk: a cohort study11
DGPCNet: anemia detection from multimodal palm, fingernails, and eye conjunctiva images using deep global pyramid convolutional network11
Managing blood supplies during natural disasters, humanitarian emergencies, and pandemics: lessons learned from COVID-1911
The National Hemophilia Foundation’s State of the Science Research Summit: the foundation of a national research blueprint for inherited bleeding disorders11
Molecular targets for the treatment of AML in the forthcoming 5th World Health Organization Classification of Haematolymphoid Tumours10
Emicizumab and unmet needs of patients with hemophilia a who are managed with replacement therapies10
Hematology in the post-COVID era: spotlight on vaccine-induced immune thrombotic thrombocytopenia and a conceptual framework (the 4P’s) for anti-PF4 diseases10
Expression and prognostic value of cytotoxic T-lymphocyte-associated 4 protein in classic Hodgkin lymphoma10
Is next-generation sequencing the future of measurable residual disease assays for Philadelphia chromosome-positive acute lymphoblastic leukemia?10
Optimizing long-term joint health in the treatment of hemophilia10
Rivaroxaban plus aspirin after lower–extremity revascularization10
Bad players in AL amyloidosis in the current era of treatment10
Thrombotic events in children and adolescent patients with SARS-CoV-2 infection: a systematic review with meta-analysis on incidence and management10
Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes10
Plain language summary: a phase 2/3 study of plasminogen, human-tvmh for the treatment of children and adults with type 1 plasminogen deficiency10
Dose optimisation of ponatinib in chronic phase chronic myeloid leukemia10
Is the occurrence of deep vein thrombosis related to the fracture site? A two-sample Mendelian randomization study9
Oral decitabine in acute myeloid leukemia: assessing efficacy, safety, and future implications for older patients9
A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors9
The association between hemoglobin level, anemia, and hypertension among adolescents in Sudan: a multicenter cross-sectional study9
Lived experience experts: a name created by us for us9
A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDS9
What is the importance of monitoring iron levels in different organs over time with magnetic resonance imaging in transfusion-dependent thalassemia patients?9
Novel therapeutics for immune thrombocytopenia: an evolving treatment landscape8
Pegcetacoplan: the first and only C3-targeted therapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria8
Sickle cell disease in gulf cooperation council countries: a systematic review8
Advances in our understanding of genetic markers and targeted therapies for pediatric LCH8
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for mucocutaneous bleeding disorders8
Real-world treatment patterns and outcomes in people with von Willebrand disease treated prophylactically with recombinant von Willebrand factor in the United States8
Long-term follow-up of patients with hairy cell leukemia in the south of Iran8
Novel mechanisms of action of emerging therapies of hereditary thrombotic thrombocytopenic purpura8
Trends of chronic lymphocytic leukemia incidence and mortality in the United States: a population-based study over the last four decades8
The impact of oral health promotion on the quality of life of children with bleeding disorders: fighting misconceptions8
Social challenges and support needs of patients with hemophilia in Pakistan: a qualitative exploratory study8
Indicators of an increased risk of therapy-related myeloid neoplasms in lymphoma patients: how can we best evaluate severe impairment of bone marrow function?8
Advancements in targeting CD30 for lymphoma therapy: a historical perspective and future directions8
Revisiting the prognostic role of FLT3 mutations in acute myelogenous leukemia7
Problems faced by people with hemophilia aged 18–35 years in social life: a qualitative study7
Exploring health disparities in diagnosing multiple myeloma7
Development of CD30 CAR-T cells in refractory or relapsed Hodgkin’s lymphoma7
Circ_0035381 contributes to the progression of acute myeloid leukemia via regulating miR-186-5p/CDCA3 pathway7
Pain in sickle cell disease: a prospective multicentre community-based cohort study in underserved Indian communities7
Genetic variant of endothelial protein C receptor genes and its serum level in B thalassemic children7
Mesenchymal stromal cells for the prophylaxis of graft-versus-host disease after hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials7
Stem cell boost for immune effector cell associated hematotoxicity in multiple myeloma: minimizing long-term complications and expanding post CAR T-cell therapy relapse options7
Advances in stem cell transplantation for Fanconi anemia7
Navigating the gap between guidelines and practical challenges in selecting first-line therapy for chronic lymphocytic leukemia7
Curative effect of motherwort combined with ethinylestradiol-cyproterone acetate on dysfunctional uterine bleeding7
An update on novel therapies for treating patients with arterial thrombosis7
Bridging the gap: how do we enroll more racial-ethnic minority patients in hematological drug trials?7
An interview with Dr Joshua Richter on his experience as an investigator for linvoseltamab-gcpt - by Reegan Burnell-Clarke (Commissioning Editor)7
Reassuring clinicians and patients using SGLT-2 inhibitors: is there a need to worry about blood complications?7
Evaluating quality-of-life outcomes during decitabine therapy in older adults with acute myeloid leukemia: overview of reported studies and assessment instruments7
Kompetitive allele specific PCR (KASP) based genotyping of sickle gene in the selected sub-ethnic tribal population of Gujarat and Madhya Pradesh7
Pomalidomide combined with dexamethasone for the treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis7
Role of volumetric analyses on [18F]FDG PET/CT in pediatric Hodgkin lymphoma7
Real-world analysis and cost-effectiveness of iron chelation therapy adherence in transfusion-dependent thalassemia6
Targeting von Willebrand disease: the current status and future directions of management therapies6
Challenges facing minimal residual disease testing for acute myeloid leukemia and promising strategies to overcome them6
Revolutionizing hypertension treatment: aprocitentan’s dual action against resistant hypertension6
How clinicians and persons with hemophilia may approach shared decision-making6
Avoiding serious treatment-emergent adverse events in Waldenström macroglobulinemia patients6
An observational study of disease management in adult patients with polycythemia vera: results from a large U.S. claims database6
May obesity increase the risk of lymphoma? Insights from genetic evidence6
Changes in circular RNA expression in acute chest syndrome and vaso-occlusive crisis in sickle cell disease: analysis of a public RNA-seq cohort6
Treatment of systemic mastocytosis with associated hematologic neoplasm: midostaurin and beyond6
NSAIDS/COXIBS for the treatment of musculoskeletal pain secondary to hemophilic arthropathy6
Efficacy and safety evaluation of eptacog beta (coagulation factor VIIa [recombinant]-jncw) for the treatment of hemophilia A and B with inhibitors6
Understanding the interplay between chronic lymphocytic leukemia and type 2 diabetes6
An evaluation of mitapivat for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency6
Identifying prognostic gene panels in acute myeloid leukemia6
Revisiting the role of measurable residual disease in FLT3 mutated acute myelogenous leukemia6
Challenges in the diagnosis of thrombotic thrombocytopenic purpura6
Exploring the genetic relationship between deep vein thrombosis and plasma protein: a new research idea6
Specifically targeting the ABL myristoyl pocket: STAMP inhibitors for chronic myeloid leukemia6
A systematic literature review of the epidemiology, quality of life, and economic burden, including disease pathways and treatment patterns of relapsed/refractory classical Hodgkin lymphoma6
Genetic insights and diagnostic challenges in inherited bone marrow failure syndromes: a comprehensive study from a low middle-income country5
Immunotherapy for myelodysplastic syndrome and acute myeloid leukemia: where do we stand?5
Polycythemia vera and metabolic syndrome: is the relationship between the two diseases more than we think?5
Effectiveness of myofascial therapy (MFT) along with traditional physiotherapy and intermittent prophylaxis on short-term improvement of joint health in hemophilic arthropathy: a randomized control tr5
Anti-tissue factor pathway inhibitors for hemophilia: are these treatments the answer to overcoming current treatment limitations?5
Vasculopathy among children and adolescents with sickle cell disease: the crosstalk with annexin A1, vitamin D, and myocardial iron overload5
Gene therapy in the treatment of hemophilia A: a systematic review and meta-analysis5
Characterizing the ideal patient for treatment with inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: a systematic literature review5
Modifiable lifestyle risk factors and survival after diagnosis with multiple myeloma5
Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia5
Incidence, prevention and management of severe infections in patients undergoing therapy for chronic lymphocytic leukemia5
Effect of hydroxyurea on erythrocyte apoptosis in hemoglobinopathy patients4
CircPTK2 promotes cell viability, cell cycle process, and glycolysis and inhibits cell apoptosis in acute myeloid leukemia by regulating miR-582-3p/ALG3 axis4
Quantifying the optimal factor VIII levels to achieve patient-centric and clinician-relevant outcomes among people with hemophilia A: a SHELF elicitation study4
The past, the present and the future of immune checkpoints inhibitors in multiple myeloma4
Cognitive impairment in hematology patients planned for chimeric antigen receptor T-cell therapy4
Comparison of blinatumomab and CAR T-cell therapy in relapsed/refractory acute lymphoblastic leukemia: a systematic review and meta-analysis4
Relationship between the ABO blood group and Rhesus factors with COVID-19 susceptibility4
Novel approaches for preventing COVID-19 infection in immunocompromised patients with hematologic malignancies4
Feasibility and outcomes of switching factor VIII therapies: post-hoc analysis of patients transitioning from older plasma-derived and first-generation recombinant factor VIII to newer third-generatio4
An evaluation of deferiprone as twice-a-day tablets or in combination therapy for the treatment of transfusional iron overload in thalassemia syndromes4
t(4;14), and revised myeloma comorbidity index as good predictors of survival for multiple myeloma4
Real-world treatment patterns and outcomes of triple-class treated patients with multiple myeloma in the United States4
Policy approach to optimize multiple myeloma treatment sequencing practices4
The role of staging in multiple myeloma4
Gene polymorphisms predicting response to hydroxyurea treatment in Bahraini patients with sickle cell disease4
Current evidence on the use of direct oral anticoagulants in patients with myeloproliferative neoplasm: a systematic review4
Copper deficiency, a rare but correctable cause of pancytopenia: a review of literature4
A deep dive into future therapies for microcytic anemias and clinical considerations4
Letter to the Editor on “Hematopoietic cell transplants in resource-poor countries: challenges and opportunities”4
CD8+CD25+ Tregs as a predictor of glucocorticoid sensitivity in patients with immune thrombocytopenia4
Magnitude of anemia and associated factors among adult patients at Baso Liben District: a cross-sectional study4
Five decades of successive establishment of hemophilia care in Thailand4
Proactive measures to reduce maternal mortality and post-partum hemorrhage in sub-Saharan Africa: the hematology perspective4
From episodic assessment to comprehensive assessment: integrating real-world monitoring in relapsed/refractory multiple myeloma4
Challenges and considerations for antifungal prophylaxis in children with acute myeloid leukemia4
Thrombo-vera: a new thrombosis risk model for polycythemia vera using modern variable selection methods4
Long non-coding RNA LOC644135 is a potential prognostic indicator in cytogenetically normal acute myeloid leukemia4
An overview of novel therapies in advanced clinical testing for acute myeloid leukemia4
Efficacy and safety profile of busulfan plus low-dose melphalan (BUMEL) versus high-dose melphalan (MEL200) as a conditioning regimen for autologous hematopoietic stem cell transplantation (auto-HSCT)4
The prognostic power of MMP-9 in diffuse large B-cell lymphoma4
An evaluation of fedratinib for adult patients with newly diagnosed and previously treated myelofibrosis3
Identifying people with acute lymphoblastic leukemia who are most suitable for treatment with inotuzumab ozogamicin: a plain language summary3
Clinical study on the prevention of deep vein thrombosis in patients with external fixation of lower limb fractures using an automatic ankle pump movement ceramic moxibustion rehabilitation device3
Challenges faced by women and girls with hemophilia/Carriers: an expert call for closing the diagnosis gap3
Assessing the impact of air pollution on anemia: a comprehensive review and meta-analysis3
The linkage between hemoglobin-to-red blood cell distribution width ratio and osteoarthritis: a study based on the national health and nutrition examination survey3
Emerging small molecular inhibitors as targeted therapies for high-risk acute myeloid leukemias3
Primary diffuse large B-cell lymphoma in the era of targeted therapies: incidence, second primary malignancy and prognosis3
The National Hemophilia Foundation State of the Science Research Summit initiative: executive summary3
Inhibitor eradication and treatment for acquired hemophilia A3
Subclinical myocardial dysfunction in essential thrombocythemia: role of global longitudinal strain3
Long-term hypercoagulability, endotheliopathy and inflammation following acute SARS-CoV-2 infection3
Mechanism regulation of endoplasmic reticulum stress in multiple myeloma cells: modulation of the UPR, UPS, autophagy, HSPs, and potential therapeutic targets3
Positron emission tomography/magnetic resonance imaging (PET/MRI) vs. gastroscopy: Can it improve detection of extranodal marginal zone lymphomas of the stomach following H. pylori treatment?3
Is intensive chemotherapy and allogeneic stem cell transplantation mandatory for curing Philadelphia chromosome-positive acute lymphoblastic leukemia in young patients in the era of multitarget agents3
Foreword: a special focus on bleeding disorders3
Next generation anticoagulants: a spotlight on the potential role of activated factors XII and XI3
Complex interaction of δ-globin variant HbA 2 -Famagusta combined with β-globin variant Hb Monroe in cis 3
Integrating an updated high-risk multiple myeloma classification into clinical practice and clinical trial epidemiology3
Masked polycythemia vera: diagnostic challenges and clinical implications3
Reduced-intensity conditioning for allogeneic transplantation in classical Hodgkin lymphoma3
Evaluating zanubrutinib for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma3
A Review of Disparities in Autologous Stem Cell Transplantation in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma3
Lower rates of maternal morbidities among pregnant women suffering from sickle cell disease who are exposed to hydroxyurea, a retrospective study from tribal area of Western India3
Evolution of the European LeukemiaNet recommendations for chronic myeloid leukemia3
Reduction of ristocetin-induced platelet aggregation (RIPA) during storage despite plasma renewal: evidence for hemostatic importance of GPIbα shedding3
The promise of novel treatments for severe chronic neutropenia3
Novel treatments for immune thrombocytopenia: targeting platelet autoantibodies3
Advances in the treatment of large granular lymphocytic leukemia2
A systematic review of histological characteristics in arterial and venous thrombi2
MiR-106b-5p, MiR-200c-3p, and MiR-146a-5p expression as putative biomarkers for disease state in primary immune thrombocytopenia2
Beyond progression-free survival (PFS): time to next treatment (TTNT) as a patient-centered metric of clinical benefit in chronic lymphocytic leukemia (CLL)2
How will genomic testing impact a clinician’s choice for managing chronic myeloid leukemia?2
Platelet indices in preeclampsia: comparative analysis with normotensive pregnant women2
Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia2
Is 50 mg/day the new standard dose of dasatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase?2
Enoxaparin adherence for venous thromboembolism prophylaxis in hospitalized patients with sickle cell disease2
The role of intraarticular injections of hyaluronic acid in joint pain relief in hemophilic arthropathy2
Addressing unmet needs in chronic myeloid leukemia in chronic phase treated with two or more tyrosine kinase inhibitors: insights from literature and Indian clinical practice2
New developments in the diagnosis and characterization of Waldenström’s macroglobulinemia2
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities to transform the care of people with hemophilia2
Correction2
Proximal complement inhibitors in paroxysmal nocturnal hemoglobinuria: an abundance of options in a rare disease2
Overexpression of SCN5A overcomes ABC transporter-mediated multidrug resistance in acute myeloid leukemia through promoting apoptosis2
Beyond linearity and static risk: re-evaluating core prognostic factors in diffuse large B-cell lymphoma2
Addressing thrombosis concerns in immune thrombocytopenia: the role of fostamatinib in immune thrombocytopenia management2
Polycythemia vera: aspects of its current diagnosis and initial treatment2
Ankle arthrodesis and total ankle replacement in patients with congenital bleeding disorders suffering from severe ankle arthropathy2
Factor first! Emergency department management of persons with hemophilia: a single-center study2
Cartilage degeneration in hemophilic arthropathy: to focus on prevention or regeneration?2
An evaluation of von Willebrand factor (recombinant) therapy for adult patients living with severe type 3 von Willebrand disease2
Dysregulated MAPK signaling pathway in acute myeloid leukemia with RUNX1 mutations2
DNA damage repair in megakaryopoiesis: molecular and clinical aspects2
Preformed anti-HLA DQA1/DQB1 DSA possibly responsible for graft failure in haploidentical stem cell transplantation2
Pregnancy and sickle cell disease: an overview of complications and suggested perinatal care2
Quality of life considerations and management in patients with myelodysplastic syndrome2
The role of gene polymorphisms in the susceptibility and therapeutic response of chronic immune thrombocytopenic purpura2
Identification and management of fetal anemia due to hemolytic disease2
To enhance the detection of aplastic anemia in primary care settings: a population-based study in Italy2
Redefining efficacy and safety endpoints for chronic lymphocytic leukemia in the era of targeted therapy2
Reduced CXCR4 expression in associated with extramedullary and predicts poor survival in newly diagnosed multiple myeloma2
Immune thrombocytopenia: a review on the pathogenetic role of immune cells2
Emicizumab: a novel drug in hemophilia A prophylaxis – a narrative review2
Global prophylaxis trends in hemophilia: a macroeconomic analysis and its association with world development indicators2
Early pharmacological intervention in acute promyelocytic leukemia: can we still improve outcomes?2
Quality of life considerations in myelodysplastic syndrome: not only fatigue2
G-CSF primary prophylaxis use and outcomes in patients receiving chemotherapy at intermediate risk for febrile neutropenia: a scoping review2
Anemia and iron overload as prognostic markers of outcomes in β-thalassemia2
Prospective patient preference study for Bruton tyrosine kinase inhibitor (BTKi) treatment attributes and factors affecting patient shared decision-making in chronic lymphocytic leukemia (CLL) and sma2
Update on iron supplementation in patients with cancer-related anemia2
Could targeted gene insertion of factor 9 be a potential durable treatment for Hemophilia B?2
The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia2
Looking to the future of gene therapy for hemophilia A and B2
“Per aspera ad astra” : the transformative contribution of glucarpidase to the improved management of delayed methotrexate elimination after high-dose therapy2
The diagnosis, natural history, and management of von Willebrand disease in women in the age of guidelines2
Post-transplant sorafenib effectively prevents relapse in FLT3-mutated acute myeloid leukemia2
Soliciting international perspectives on an American national research agenda for inherited bleeding disorders2
Subanesthetic ketamine: the way forward for pain management in sickle cell disease patients?2
0.093782901763916